Inhibition of IL-17A in atherosclerosis
X Cheng, S Taleb, J Wang, TT Tang, J Chen... - Atherosclerosis, 2011 - Elsevier Apo E -/- mice were treated with either rat anti-mouse IL-17A, mouse anti-mouse IL-17A or
isotype-matched control antibodies for 12 weeks (n = 8-10 per group). Ldlr -/- mice were transplanted
with IL-17A-deficient or wild type bone marrow (n = 8 per group). Rat anti-mouse IL-17A ...
Apo E / mice were treated with either rat anti-mouse IL-17A, mouse anti-mouse IL-17A or isotype-matched control antibodies for 12 weeks (n = 8 10 per group). Ldlr / mice were transplanted with IL-17A-deficient or wild type bone marrow (n = 8 per group). Rat anti-mouse IL-17A treatment obviously reduced plaque size by 43% (p < 0.01) without evidence of reduced IL-17A signaling. In contrast, mouse anti-mouse IL-17A treatment and IL-17A deficiency in bone marrow cells did not alter lesion size despite significant reduction of IL-17A production.
Inhibition of IL-17A signaling does not alter lesion development in Th1-biased C57BL/6 Apo E / and Ldlr / mice with already low levels of IL-17A production. Alteration of lesion development after repeated injections of rat anti-mouse IL-17A antibody in Apo E / mice could not be attributed to blockade of IL-17A signaling.
More Details:
Inhibition of IL-17A in atherosclerosis |
